Mary Cushman: Unprovoked VTE as a Marker of Increased Cardiovascular Mortality Risk
Mary Cushman, University Distinguished Professor and Vice Chair at the University of Vermont, shared Debora Kamin Mukaz‘s post on LinkedIn, adding:
“Alert! People with unprovoked VTE have double the risk of death than those without VTE.
Their leading cause of death is circulatory disease.
When you are seeing patients with VTE think big picture.
Start a statin if indicated.
Get bold pressure less than 130.
Talk about smoking cessation.”
Debora Kamin Mukaz, Assistant Professor of Medicine at Larner College of Medicine at the University of Vermont, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Journal of Thrombosis and Haemostasis:
“We published a new paper on long-term mortality and causes of death after venous thromboembolism (VTE) in Journal of Thrombosis and Haemostasis (JTH).
People with any VTE were approximately 3 times more likely to die over 5 years than those without VTE.
The 5-year mortality risk were approximately 6-fold for cancer-provoked VTE and 2-fold for unprovoked and other-provoked VTE.
Those with cancer-provoked VTE were most likely to die of cancer, but circulatory diseases were the main causes of death after all other types of VTE.
This suggests that enhanced cardiovascular prevention in patients with VTE might delay mortality.”
Title: Long-term mortality and causes of death after venous thromboembolism: findings from the Atherosclerosis Risk in Communities Cohort Study
Authors: Debora Kamin Mukaz, Aixin Li, Weihua Guan, Rui Cao, Lingfeng Huo, Weihong Tang, Pamela L Lutsey, Neil A Zakai, Aaron R Folsom, Mary Cushman
Other posts featuring Mary Cushman on Hemostasis Today.
-
Jun 4, 2026, 16:17Nada Fahd: Immune Thrombocytopenia (ITP) – Outpatient vs Inpatient Management
-
Jun 4, 2026, 16:16Saoud Hassan: Hemostasis and Blood Coagulation Pathway – Simplified
-
Jun 4, 2026, 16:15Farooq Khan: Vacuuming Blood Clots in Seconds
-
Jun 4, 2026, 16:14Kayla Garrett: Confirming Or Excluding APS Relies On Accurate Lupus Anticoagulant Testing
-
Jun 4, 2026, 16:14Scott Colton: Exploring the Key Differences Between Anticoagulant and Antiplatelet Medications
-
Jun 4, 2026, 16:13Wolfgang Miesbach: Is Bone Health a Silent Comorbidity In Haemophilia and VWD?
-
Jun 4, 2026, 15:35Carolina La Mura: Insights from the LATAM Hemophilia Forum 2026
-
Jun 4, 2026, 15:25Heba Youssef: Anticoagulation Bridging – A Clinical Summary Every Practitioner Should Know
-
Jun 4, 2026, 15:10Dipanjana Datta: Genetic Spectrum of Hemophilia and Carrier Screening in Families of Persons with Hemophilia